Goldman Sachs Maintains Buy on ArriVent BioPharma, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Johnson has maintained a Buy rating on ArriVent BioPharma and raised the price target from $28 to $38.
September 10, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has reaffirmed its Buy rating on ArriVent BioPharma and increased the price target from $28 to $38, indicating confidence in the company's future performance.
The increase in price target from $28 to $38 by a reputable firm like Goldman Sachs suggests a positive outlook for ArriVent BioPharma. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100